NCT03746301View on ClinicalTrials.gov

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation

CompletedOBSERVATIONAL
Enrollment

924

Participants

Timeline

Start Date

December 3, 2018

Primary Completion Date

July 28, 2021

Study Completion Date

December 15, 2021

Conditions
Non-valvular Atrial Fibrillation (NVAF)
Interventions
DRUG

Rivaroxaban(Xarelto,BAY 59-7939)

10mg, 15mg and 20 mg film-coated tablets

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY